Data completeness
3/8 — Basic
BETAMETHASONE VALERATE (betamethasone valerate) by Sandoz is clinical pharmacology: topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. Approved for atopic eczema, hand eczema, psoriasis.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Betamethasone valerate is a mid-potency topical corticosteroid lotion developed by Sandoz for treatment of inflammatory skin conditions including atopic eczema, hand eczema, and psoriasis. It works through anti-inflammatory, antipruritic, and vasoconstrictive mechanisms that reduce skin inflammation and itching. The drug is currently in pre-launch phase as a topical formulation.
$0.004BPart D
Pre-LaunchPre-launch stage indicates active commercial build-out with opportunities in product marketing, market access, and field team development.
Mechanism of Action
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Indications (3)
Investigational (3)
Worked on BETAMETHASONE VALERATE at Sandoz? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.